Leucovorin Calcium 5 mg Tablet, 30-count — NDC 42806-358-30 (Billing 42806-0358-30)
This is a package of 30 tablets of Leucovorin Calcium 5 mg Tablet from Epic Pharma LLC, marketed since Apr 2020 and currently FDA-listed; retail pharmacies pay about $0.3300 per tablet (NADAC). It is the main listing for this product, which comes in 2 package sizes.
NDC database record
One package, one record: these facts belong to NDC 42806-358-30 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 42806 labeler · 358 product · 30 package
- Package marketed since
- Apr 16, 2020
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Billing quantity
- 30 EA per package
- Barcode (UPC)
- 0342806133217, 0342806359259, 0342806134245, 0342806358016
- Medicaid fills, this package
- 6,777 prescriptions in the last four reported quarters
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 044539
- GCN: 87558
- GPI-14 (Medi-Span): 21755040100310
- HICL (First Databank): 001063
- AHFS class code: 91:04.12.00
- RxCUI (RxNorm): 197860
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 6, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
RxNorm drug class
This medicine belongs to the Folate Analog class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
Leucovorin is used to prevent harmful effects of methotrexate (a cancer chemotherapy medication) or to treat an overdose of methotrexate or similar medications. It is also used to treat people who have an inherited condition that prevents folate from reaching the brain. Leucovorin is in a class of medications called folic acid analogs. It works by protecting healthy cells from the effects of methotrexate or similar medications while allowing methotrexate to enter and kill cancer cells.
Read the full MedlinePlus article ↗- It depends on which chemotherapy you're getting. If you're on methotrexate, leucovorin acts like a protective antidote — it steps in to restore the folate your cells need, shieldin...
- Why am I being given leucovorin alongside my chemotherapy?
- Yes — you can take Leucovorin Calcium tablets with or without food. Food isn't expected to meaningfully affect how your body absorbs it. If you have trouble swallowing the tablet,...
- Can I take the leucovorin tablet with food?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Leucovorin Calcium — tap one for details:
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 6, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per ea | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | $0.330 | $9.90 / 30 tablets |
| Medicaid paysCMS SDUD · 12 mo | $0.5912 | $17.74 / 30 tablets |
| Medicare drug plans payPart D · Q2 2026 | $0.7402 | $22.21 / 30 tablets |
Where does this data come from?
- CMS NADAC weekly file · file of Sep 30, 2026
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · through Q1 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Marketing end | Status |
|---|---|---|---|---|---|---|
| 42806-0358-01 42806-358-01 | 100 TABLET in 1 BOTTLE | $0.3300 / ea | $33.00 | 2020-04-16 | — | Active |
| 42806-0358-30 You're viewing this Main listing | 30 TABLET in 1 BOTTLE | $0.3300 / ea | $9.90 | 2020-04-16 | — | Active |
You're viewing the smallest of 2 pack sizes for this product.
This pack effectively ties for the lowest per-ea cost of the 2 priced pack sizes ($0.3300 NADAC).
This pack accounts for about 48% of this product's recent Medicaid fills; most go to the 100 tablets pack. See all packs ↓
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 42806-0358-01?
What NDC number is used to bill for this package of Leucovorin Calcium 5 mg Tablet?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Leucovorin Calcium 5 mg 00054-4496-13 | Hikma | 30 tablets | $0.330 | AB | Availability likely | — |
| Leucovorin Calcium 5 mg 00054-8496-19 | Hikma | 50 tablets | $0.330 | AB | Availability likely | — |
| Leucovorin Calcium 5 mg 00555-0484-01 | Teva | 30 tablets | $0.330 | AB | Availability likely | — |
| Leucovorin Calcium 5 mgthis 42806-0358-30 | Epic | 30 tablets | $0.330 | AB | Availability likely | — |
| Leucovorin Calcium 5 mg 50742-0181-01 | Ingenus | 100 tablets | $0.330 | AB | Availability likely | — |
| Leucovorin Calcium 5 mg 69315-0184-01 | Leading | 100 tablets | $0.330 | AB | Availability likely | — |
| Lederle Leucovorin 5 mg 00069-5886-24 | Pfizer | 24 tablets | — | — | FDA listed | — |
| Leucovorin Calcium 5 mg 71205-0908-00 | Proficient | 100 tablets | — | AB | FDA listed | — |
| Lederle Leucovorin 5 mg 73591-5886-01 | FARMASIERRA | 100 tablets | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file · file of Sep 30, 2026
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Oct 3, 2026
What it looks like
Where does this data come from?
- FDA label on DailyMed · label index refreshed Oct 6, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Leucovorin inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 3SY5LH9PMK
Anhydrous lactose is a milk sugar with no water content. It acts as a filler and binder in tablets and capsules, adding bulk and helping ingredients stick together.
-
UNII M28OL1HH48
Croscarmellose sodium is a plant-based substance derived from cellulose. It acts as a disintegrant, helping tablets and capsules break down quickly in the digestive system so the medicine can be absorbed.
-
UNII R4OXA9G5BV
A fatty acid salt derived from palm and stearic oils. It works as a lubricant and glidant to help the medicine flow smoothly during manufacturing and prevent ingredients from sticking together.
-
UNII OP1R32D61U
Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
-
UNII ETJ7Z6XBU4
Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
5 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 6, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Epic Pharma LLC labeler code 42806
- Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg Tablet NDC 42806-341-01
- Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg Tablet NDC 42806-343-01
- Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and 5 mg; 5 mg; 5 mg; 5 mg Tablet NDC 42806-344-01
- Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg Tablet NDC 42806-345-01
- Bupropion Hydrochloride XL 150 mg Tablet, Extended Release NDC 42806-348-05
- Bupropion Hydrochloride XL 300 mg Tablet, Extended Release NDC 42806-349-05
- Leucovorin Calcium 25 mg Tablet NDC 42806-359-25
- Doxycycline Hyclate 20 mg Tablet NDC 42806-362-01
- Oseltamivir Phosphate for Oral Suspension 6 mg/mL Powder, For Suspension NDC 42806-363-13
- Deferasirox Oral Granules 90 mg Granule NDC 42806-371-30
- Deferasirox Oral Granules 180 mg Granule NDC 42806-372-30
- Deferasirox Oral Granules 360 mg Granule NDC 42806-373-30
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Leucovorin calcium tablets are indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Leucovorin calcium tablets are intended for oral administration. Because absorption is saturable, oral administration of doses greater than 25 mg is not recommended. Impaired Methotrexate Elimination or Inadvertent Overdosage: Leucovorin rescue should begin as soon as possible after an inadvertent overdosage and within 24 hours of methotrexate administration when there is delayed excretion (see WARNINGS ) 2 .
Leucovorin 15 mg (10 mg/m 2 ) should be administered IM, IV, or PO every 6 hours until serum methotrexate level is less than 10 -8 M. In the presence of gastrointestinal toxicity, nausea or vomiting, leucovorin should be administered parenterally. Serum creatinine and methotrexate levels should be determined at 24-hour intervals.
If the 24 hour serum creatinine has increased 50% over baseline or if the 24 hour methotrexate level is greater than 5 x 10 -6 M or the 48 hour level is greater than 9 x 10 -7 M, the dose of leucovorin should be increased to 150 mg (100 mg/m 2 ) IV every 3 hours until the methotrexate level is less than 10 -8 M. Doses greater than 25 mg should be given parenterally (see ). Hydration (3 L/d) and urinary alkalinization with sodium bicarbonate should be employed concomitantly.
The bicarbonate dose should be adjusted to maintain the urine pH at 7 or greater. The recommended dose of leucovorin to counteract hematologic toxicity from folic acid antagonists with less affinity for mammalian dihydrofolate reductase than methotrexate (i.e., trimethoprim, pyrimethamine) is substantially less, and 5 to 15 mg of leucovorin per day has been recommended by some investigators. Patients who experience delayed early methotrexate elimination are likely to develop reversible non-oliguric renal failure.
In addition to appropriate leucovorin therapy, these patients require continuing hydration and urinary alkalinization, and close monitoring of fluid and electrolyte status, until serum methotrexate level has fallen below 0.05 micromolar and the renal failure has resolved. Some patients will have abnormalities in methotrexate elimination or renal function following methotrexate administration, which are significant but less severe. These abnormalities may or may not be associated with significant clinical toxicity.
If significant clinical toxicity is observed, leucovorin rescue should be extended for an additional 24 hours (total of 14 doses over 84 hours) in subsequent courses of therapy. The possibility that the patient is taking other medications which interact with methotrexate (e.g., medications which may interfere with methotrexate elimination or binding to serum albumin) should always be reconsidered when laboratory abnormalities or clinical toxicities are observed.
⛔ Contraindications ▾
CONTRAINDICATIONS Leucovorin is improper therapy for pernicious anemia and other megaloblastic anemias secondary to the lack of Vitamin B 12 . A hematologic remission may occur while neurologic manifestations continue to progress.
⚠️ Warnings ▾
WARNINGS In the treatment of accidental overdosage of folic acid antagonists, leucovorin should be administered as promptly as possible. As the time interval between antifolate administration (e.g., methotrexate) and leucovorin rescue increases, leucovorin’s effectiveness in counteracting hematologic toxicity decreases. Monitoring of the serum methotrexate concentration is essential in determining the optimal dose and duration of treatment with leucovorin.
Delayed methotrexate excretion may be caused by a third space fluid accumulation (i.e., ascites, pleural effusion), renal insufficiency, or inadequate hydration. Under such circumstances, higher doses of leucovorin or prolonged administration may be indicated. Doses higher than those recommended for oral use must be given intravenously.
Leucovorin may enhance the toxicity of fluorouracil. Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil. 1 Concomitant granulocytopenia and fever were present in some but not all of the patients.
The concomitant use of leucovorin with trimethoprim-sulfamethoxazole for the acute treatment of Pneumocystis carinii pneumonia in patients with HIV infection was associated with increased rates of treatment failure and mortality in a placebo-controlled study.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS Allergic sensitization, including anaphylactoid reactions and urticaria, has been reported following the administration of both oral and parenteral leucovorin.
🔄 Drug Interactions ▾
Drug Interactions Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible children. Preliminary animal and human studies have shown that small quantities of systemically administered leucovorin enter the CSF primarily as 5-methyltetrahydrofolate and, in humans, remain 1 to 3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration. However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate.
Leucovorin may enhance the toxicity of fluorouracil (see WARNINGS ).
🤰 Pregnancy ▾
Pregnancy Teratogenic Effects: Pregnancy Category C. Animal reproduction studies have not been conducted with leucovorin. It is also not known whether leucovorin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Leucovorin should be given to a pregnant woman only if clearly needed.
🧒 Pediatric Use ▾
Pediatric Use See Drug Interactions subsection.
🆘 Overdosage ▾
OVERDOSAGE Excessive amounts of leucovorin may nullify the chemotherapeutic effect of folic acid antagonists.
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Leucovorin is a racemic mixture of the diastereoisomers of the 5-formyl derivative of tetrahydrofolic acid. The biologically active compound of the mixture is the (-)- L -isomer, known as Citrovorum factor, or (-)-folinic acid. Leucovorin does not require reduction by the enzyme dihydrofolate reductase in order to participate in reactions utilizing folates as a source of “one-carbon” moieties.
Following oral administration, leucovorin is rapidly absorbed and enters the general body pool of reduced folates. The increase in plasma and serum folate activity (determined microbiologically with Lactobacillus casei ) seen after oral administration of leucovorin is predominantly due to 5-methyltetrahydrofolate. Twenty normal men were given a single, oral 15 mg dose (7.5 mg/m 2 ) of leucovorin calcium and serum folate concentrations were assayed with L. casei.
Mean values observed (± one standard error) were: a) Time to peak serum folate concentration: 1.72 ± 0.08 hours, b) Peak serum folate concentration achieved: 268 ± 18 ng/mL, c) Serum folate half-disappearance time: 3.5 hours. Oral tablets yielded areas under serum folate concentration-time curves (AUCs) that were 12% greater than equal amounts of leucovorin given intramuscularly and equal to the same amounts given intravenously. Oral absorption of leucovorin is saturable at doses above 25 mg.
The apparent bioavailability of leucovorin was 97% for 25 mg, 75% for 50 mg and 37% for 100 mg.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Leucovorin Calcium Tablets USP, 5 mg are off-white, round biconvex tablets, debossed “Є” above “ 358 ” on one side and bisected on the other side and are supplied as follows. NDC 42806-358-30 Bottles of 30 NDC 42806-358-01 Bottles of 100 Leucovorin Calcium Tablets USP, 10 mg are off-white, round biconvex tablets, debossed “Є” above “ 133 ” on one side and bisected on the other side and are supplied as follows. NDC 42806-133-21 Bottles of 12 NDC 42806-133-24 Bottles of 24 Leucovorin Calcium Tablets USP, 15 mg are off-white, round biconvex tablets, debossed “Є” above “ 134 ” on one side and bisected on the other side and are supplied as follows.
NDC 42806-134-24 Bottles of 24 Leucovorin Calcium Tablets USP, 25 mg are off-white, round biconvex tablets, debossed “Є” above “ 359 ” on one side and bisected on one side and plain on the other side and are supplied as follows. NDC 42806-359-25 Bottles of 25 Store at Controlled Room Temperature 15° to 30°C (59° to 86°F). Protect from light and moisture.
REFERENCES 1. Grem JL, Shoemaker DD, Petrelli NJ, Douglas HO. Severe and fatal toxic effects observed in treatment with high- and low-dose leucovorin plus 5-fluorouracil for colorectal carcinoma.
Cancer Treat Rep 1987; 71: 1122. 2. Link MP, Goorin AM, Miser AW et al.
The effect of adjuvant chemotherapy on relapse-free survival patients with osteosarcoma of the extremity. N Engl J Med 1986; 314:1600 – 1606. Distributed by: Epic Pharma, LLC Laurelton, NY 11413 Rev.
06-2023-00 MF358REV06/23 OE2930
📋 Description ▾
DESCRIPTION Leucovorin calcium tablets USP contain either 5 mg, 10 mg, 15 mg or 25 mg leucovorin as the calcium salt of N -[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]- L -glutamic acid. This is equivalent to either 5.4 mg, 10.8 mg, 16.21 mg or 27.01 mg of anhydrous leucovorin calcium, respectively. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, lactose anhydrous, magnesium stearate, and microcrystalline cellulose.
Leucovorin is a water-soluble form of reduced folate in the folate group; it is useful as an antidote to drugs which act as folic acid antagonists. These tablets are intended for oral administration only. The structural formula of leucovorin calcium is: C 20 H 21 CaN 7 O 7 MW 511.51 leucovorin\structural.jpg
⚠️ Precautions ▾
PRECAUTIONS General Parenteral administration is preferable to oral dosing if there is a possibility that the patient may vomit or not absorb the leucovorin. Leucovorin has no effect on other established toxicities of methotrexate such as the nephrotoxicity resulting from drug and/or metabolite precipitation in the kidney. Drug Interactions Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of seizures in susceptible children.
Preliminary animal and human studies have shown that small quantities of systemically administered leucovorin enter the CSF primarily as 5-methyltetrahydrofolate and, in humans, remain 1 to 3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration. However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate. Leucovorin may enhance the toxicity of fluorouracil (see WARNINGS ).
Pregnancy Teratogenic Effects: Pregnancy Category C. Animal reproduction studies have not been conducted with leucovorin. It is also not known whether leucovorin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
Leucovorin should be given to a pregnant woman only if clearly needed. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when leucovorin is administered to a nursing mother.
Pediatric Use See Drug Interactions subsection.
🍼 Nursing Mothers ▾
Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when leucovorin is administered to a nursing mother.
📄 Package Label / Principal Display Panel ▾
PACKAGE/LABEL PRINCIPAL DISPLAY PANEL - Leucovorin Calcium Tablets USP, 5 mg 100ct 5mg-100ct
PACKAGE/LABEL PRINCIPAL DISPLAY PANEL - Leucovorin Calcium Tablets USP, 10 mg 12ct 10mg-12ct
PACKAGE/LABEL PRINCIPAL DISPLAY PANEL - Leucovorin Calcium Tablets USP, 15 mg 24ct 15mg-24ct
PACKAGE/LABEL PRINCIPAL DISPLAY PANEL - Leucovorin Calcium Tablets USP, 25 mg 25ct 25mg-25ct